140 results found.

Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Onc Clinical Trial using AMG 232

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors.
AMG 232

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Neoplasms Clinical Trial using BI 860585; exemestane; paclitaxel

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours.
BI 860585; exemestane; paclitaxel

Neoplasms Clinical Trial using MPDL3280A; bevacizumab [Avastin]; FOLFOX; carboplatin; paclitaxel; pemetrexed; nab-paclitaxel

Genentech - Recruiting 18 years or older.
- A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors.
MPDL3280A; bevacizumab [Avastin]; FOLFOX; carboplatin; paclitaxel; pemetrexed; nab-paclitaxel

Solid Tumors Clinical Trial using thioureidobutyronitrile

Cellceutix Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors.
thioureidobutyronitrile

Cancer, or Solid Tumor Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors.
MK-3475

HIV Infection, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Solid Cancers Clinical Trial using letrozole; fulvestrant; GDC-0032

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer.
letrozole; fulvestrant; GDC-0032

Solid Tumour Clinical Trial using GDC-0994

Genentech - Recruiting 18 years or older.
- An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors.
GDC-0994

Neoplasms Clinical Trial using MEHD7945A; cobimetinib

Genentech - Recruiting 18 years or older.
- A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MEHD7945A and GDC-0973 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MUTANT KRAS.
MEHD7945A; cobimetinib

Neoplasms Clinical Trial using GDC-0973; GDC-0068

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors.
GDC-0973; GDC-0068

Solid Cancers Clinical Trial using paclitaxel; docetaxel; GDC-0068; mFOLFOX6; enzalutamide

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose-escalation Study of the Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors.
paclitaxel; docetaxel; GDC-0068; mFOLFOX6; enzalutamide

Neoplasms Clinical Trial using BAY1125976

Bayer - Recruiting 18 years or older.
- A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors.
BAY1125976

Solid Cancers Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies.
MPDL3280A

Solid Tumors, Melanoma, or Metastatic Colorectal Cancer Clinical Trial using CEP-32496

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal Cancer With BRAF Mutation in Phase 2.
CEP-32496

Solid Tumors Clinical Trial using CEP-37440

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors.
CEP-37440

Hematologic Malignancies, or Solid Tumors Clinical Trial using omacetaxine mepesuccinate

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors.
omacetaxine mepesuccinate

Advanced Solid Tumors Clinical Trial using ABT-165; paclitaxel; FOLFIRI

AbbVie - Recruiting 18 years or older.
- A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors.
ABT-165; paclitaxel; FOLFIRI

Cholangiocarcinoma, Chondrosarcoma, Glioma, or Advanced Solid Tum Clinical Trial using AG-120

Agios Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation.
AG-120

Tumor or Lymphoma Clinical Trial using JNJ-42756493

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
JNJ-42756493

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors..
PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Advanced Solid Tumors Clinical Trial using TAS-102 with a light tracer dose of [14C]FTD; TAS-102 with a light tracer dose of [14C] TPI; TAS-102 tablets

Taiho Pharma USA, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors.
TAS-102 with a light tracer dose of [14C]FTD; TAS-102 with a light tracer dose of [14C] TPI; TAS-102 tablets

Advanced Solid Tumors (Excluding Breast Cancer) Clinical Trial using TAS-102 tablets; TAS-102 oral solution

Taiho Pharma USA, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI.
TAS-102 tablets; TAS-102 oral solution

Neoplasms Clinical Trial using zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase Ia/Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered Either Alone (Part A) or in Combination With Cetuximab (Part B) or in Combination With Erlotininb (Part C) in Patients With Metastatic and/or Locally Advanced Malignant HER3-positive Solid Tumors of Ephitelian Cell Origin.
zirconium-89-labeled RO5479599; RO5479599; cetuximab; erlotinib

Neoplasms Clinical Trial using RO5509554; paclitaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors..
RO5509554; paclitaxel

Neoplasms Clinical Trial using RO5429083

Hoffmann-La Roche - Recruiting 18 years or older.
- Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors.
RO5429083

Malignant Solid Neoplasms Clinical Trial using Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Centre Leon Berard - Recruiting 18 years or older.
- A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors.
Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Advanced Solid Tumors Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors.
LEE011

Solid Tumors and Advanced Endometrial Cancer, Endometrial Cancer, Clinical Trial using TKI258

Novartis - Recruiting 18 years or older.
- A Phase II, Open-label, Single-arm, Non-randomized, Multi-center Study to Evaluate the Efficacy of Oral TKI258 as Second-line Therapy in Patients With Either FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer.
TKI258

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors.
calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Solid Tumors, or Metastatic Disease Clinical Trial using Histological biopsy procedure

UMC Utrecht - Recruiting 18 years or older.
- Protocol to Obtain Tumor Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer to Improve Selection for Clinical Trials. (CPCT - 05 Biopsy Protocol Patient Selection).
Histological biopsy procedure

Neoplasms Clinical Trial using Refametinib (BAY86-9766); Gemcitabine

Bayer - Recruiting 18 years or older.
- A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors.
Refametinib (BAY86-9766); Gemcitabine

Advanced Solid Tumors,, or Metastatic Solid Tumors Clinical Trial using BGJ398; BYL719

Novartis - Recruiting 18 years or older.
- A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors.
BGJ398; BYL719

Cancer, or Advanced Solid Tumors Clinical Trial using Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

VU University Medical Center - Recruiting 18 years or older.
- Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies..
Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

Solid Tumor, or Non-small Cell Lung Cancer Clinical Trial using MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Merck Sharp & Dohme Corp. - Recruiting 20 years or older.
- A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer.
MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Neoplasms, or Lymphoma Clinical Trial using MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Single-agent MK-1775, a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors.
MK-1775

Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Brea Clinical Trial using BMN 673

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations.
BMN 673

Neoplasms Clinical Trial using 5-Fluoro-2-Deoxycytidine; Tetrahydrouridine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Trial of Oral 5-Fluoro-2-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.
5-Fluoro-2-Deoxycytidine; Tetrahydrouridine

Solid Tumors Clinical Trial using Bevacizumab; Dasatinib

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors.
Bevacizumab; Dasatinib

Solid Tumors, Brain Tumors, Sarcoma, Wilm's Tumor, or Rhabdomyosa Clinical Trial using NK cellular therapy; rhIL-15

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 29 years.
- A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors.
NK cellular therapy; rhIL-15

Sarcoma, Stomach Neoplasms, or Neoplasms Clinical Trial using Pazopanib; ARQ 197

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors.
Pazopanib; ARQ 197

Neoplasms Clinical Trial using Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors.
Temozolomide; Everolimus; Carboplatin; Trametinib DMSO; ABT-888; MK-1775

Advanced Solid Tumors Clinical Trial using TAS-114 + S-1

Taiho Pharmaceutical Co., Ltd. - Recruiting 20 years or older.
- A Phase 1 Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors.
TAS-114 + S-1

Neoplasms Clinical Trial using RO6895882

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION, PHASE I STUDY WITH AN EXPANSION PHASE, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6895882, AN IMMUNOCYTOKINE, CONSISTING OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA) ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS.
RO6895882

Neoplasms Clinical Trial using RO5520985

Hoffmann-La Roche - Recruiting 18 years or older.
- An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors..
RO5520985

Solid Tumors, or Advanced Cancer Clinical Trial using Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance.
Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

Solid Tumors, Lymphoma, or Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib; Gefitinib

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies.
LY2875358; Erlotinib; Gefitinib

Malignant Solid Tumour, or Gastroesophageal Cancer Clinical Trial using Tivantinib; FOLFOX

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II).
Tivantinib; FOLFOX

Neoplasms, or Lymphoma Clinical Trial using Part 1: JNJ-42756493; Part 2: JNJ-42756493

Janssen Research & Development, LLC - Recruiting 20 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
Part 1: JNJ-42756493; Part 2: JNJ-42756493

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN9708

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1 Study of [14C]-MLN9708 to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas.
MLN9708

Neoplasm Malignant Clinical Trial using Cabazitaxel (XRP6258)

Sanofi - Recruiting 18 years or older.
- Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment.
Cabazitaxel (XRP6258)

Advanced Solid Tumors, or Lymphomas Clinical Trial using Camptothecin-20-O-Propionate Hydrate (CZ48)

New Mexico Cancer Care Alliance - Recruiting 18 years or older.
- Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma.
Camptothecin-20-O-Propionate Hydrate (CZ48)

Fallopian Tube, Primary Peritoneal Cancer, or Solid Tumors (eg Br Clinical Trial using ABT-767

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
ABT-767

Solid Tumors, or Hepatic Dysfunction Clinical Trial using Trametinib

University Health Network, Toronto - Recruiting 18 years or older.
- A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction.
Trametinib

Advanced Solid Tumors Clinical Trial using Lapatinib and bortezomib

Georgetown University - Recruiting 18 years or older.
- A Phase I Study of the HER1, HER2 Dual Kinase Inhibitor, Lapatinib Plus the Proteosomal Inhibitor Bortezomib in Patients With Advanced Malignancies.
Lapatinib and bortezomib

Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Adva Clinical Trial using FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Amgen - Recruiting 18 years or older.
- A Phase 2 Open Label Extension Study of Conatumumab and AMG 479.
FOLFOX6; Conatumumab; Ganitumab; Bevacizumab

Neoplasms Clinical Trial using BAY1163877

Bayer - Recruiting 18 years or older.
- An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors.
BAY1163877

Solid Tumors, Cancer, or NSCLC Clinical Trial using cabozantinib capsules; cabozantinib tablets

Exelixis - Recruiting 20 years or older.
- Phase 1 Multiple Ascending Dose Study of XL184 Monotherapy in Japanese Subjects With Advanced or Metastatic Solid Tumors.
cabozantinib capsules; cabozantinib tablets

Oncology Clinical Trial using BAY94-9343; BAY94-9343 (Expansion); BAY94-9343 (1.8 mg/kg); BAY94-9343 (2.2 mg/kg)

Bayer - Recruiting 18 years or older.
- An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors.
BAY94-9343; BAY94-9343 (Expansion); BAY94-9343 (1.8 mg/kg); BAY94-9343 (2.2 mg/kg)

Advanced Solid Tumors, or Lymphoma Clinical Trial using MLN8237

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas.
MLN8237

Solid Tumors, or Lymphoma Clinical Trial using alisertib; esomeprazole; rifampin

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas.
alisertib; esomeprazole; rifampin

Neoplasms Clinical Trial using Cobimetinib; MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors.
Cobimetinib; MPDL3280A

Breast Neoplasms Clinical Trial using Sorafenib (Nexavar, BAY43-9006); Eribulin

Bayer - Recruiting 18 years or older.
- A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors.
Sorafenib (Nexavar, BAY43-9006); Eribulin

Advanced Malignant Solid Tumors Clinical Trial using MLN7243

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors.
MLN7243

BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, or Unspecified Ad Clinical Trial using veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1 Trial of ABT-888 and SCH727965 Without or With Carboplatin in Patients With Advanced Solid Tumors.
veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using dabrafenib; pazopanib hydrochloride; Correlative studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors.
dabrafenib; pazopanib hydrochloride; Correlative studies

Advanced Solid Tumors Clinical Trial using MEDI4736

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Japanese Patients With Advanced Solid Tumors.
MEDI4736

Advanced Solid Tumor, or Lymphomas Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011

Solid Tumors Clinical Trial using MK-8242

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 in Patients With Advanced Solid Tumors.
MK-8242

Solid Tumors Clinical Trial using LCL161; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors.
LCL161; Paclitaxel

Various Advanced Cancer Clinical Trial using BMS-986115

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors.
BMS-986115

Solid Tumors Clinical Trial using Sym004

Merck KGaA - Recruiting 20 years or older.
- A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors.
Sym004

KRAS Mutated Colorectal Adenocarcinoma, Metastatic Pancreatic Ade Clinical Trial using MEK162 + AMG 479

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Open-label, Multi-center Study of the Combination of MEK162 Plus AMG 479 (Ganitumab) in Adult Patients With Selected Advanced Solid Tumors.
MEK162 + AMG 479

Cancer, Advanced Solid Tumors Clinical Trial using BBI503

Boston Biomedical, Inc - Recruiting 18 years or older.
- A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors.
BBI503

Advanced Solid Tumor, or Lymphoma Clinical Trial using DS-3032

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas.
DS-3032

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using nanosomal docetaxel lipid suspension; pharmacological study

USC/Norris Comprehensive Cancer Center - Recruiting 18 years to 64 years.
- An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors.
nanosomal docetaxel lipid suspension; pharmacological study

Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Can Clinical Trial using DCVax-Direct

Northwest Biotherapeutics - Recruiting 18 years to 75 years.
- A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS.
DCVax-Direct

Solid Tumors Clinical Trial using uncaria tomentosa (cat's claw)

Faculdade de Medicina do ABC - Recruiting 18 years or older.
- Phase II Clinical Trial of Uncaria Tomentosa (Cat's Claw) in Patients With Advanced Solid Tumors.
uncaria tomentosa (cat's claw)

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma Clinical Trial using Urelumab (BMS-663513)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL).
Urelumab (BMS-663513)

Cancer Clinical Trial using Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors.
Paclitaxel; 5-Fluorouracil (5-FU); Carboplatin; Leucovorin; Irinotecan; BMS-906024

CANCER, NOS Clinical Trial using Lirilumab; Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors.
Lirilumab; Ipilimumab

Advanced or Metastatic Solid Tumors, or Advanced or Metastatic Br Clinical Trial using Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

University of Utah - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.
Azacitidine (Vidaza); Nab-paclitaxel (Abraxane)

CANCER,NOS Clinical Trial using Lirilumab; Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Patients With Advanced Solid Tumors.
Lirilumab; Nivolumab

Neoplasms by Site Clinical Trial using BMS-986016; BMS-936558

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.
BMS-986016; BMS-936558

Solid Tumors and Non-Hodgkin's Lymphoma Clinical Trial using LY2780301; Gemcitabine

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer.
LY2780301; Gemcitabine

Solid Tumors Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors.
INC280

Metastatic Solid Tumors Clinical Trial using MLN1117

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease.
MLN1117

Tumor, Solid Clinical Trial using MK-8353

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203)).
MK-8353

Advanced Solid Tumors Clinical Trial using MP-3549.1

Mallinckrodt - Recruiting 18 years or older.
- A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MP-3549.1 in Subjects With Advanced Solid Tumors.
MP-3549.1

Neoplasms Clinical Trial using IMC-3C5

Eli Lilly and Company - Recruiting 18 years or older.
- Phase 1 Study of the Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available.
IMC-3C5

Neoplasms, Brain Clinical Trial using Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

GlaxoSmithKline - Recruiting 1 Month to 17 years.
- Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation Positive Solid Tumors.
Dabrafenib 3 mg/kg; Dabrafenib 3.75 mg/kg; Dabrafenib 4.5 mg/kg; Dabrafenib 1.5 mg/kg; Dabrafenib 2.25 mg/kg; Dabrafenib (Final selected dose from Part 1)

Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Ad Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 18 years or older.
- Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies.
ADI-PEG 20

Advanced Solid Tumor Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors.
INC280

Neoplasms Clinical Trial using Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Bayer - Recruiting 18 years or older.
- A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment.
Regorafenib (Stivarga, BAY73-4506); Cetuximab (ERBITUX)

Colorectal Neoplasms, Colorectal Carcinoma, or Colorectal Tumors Clinical Trial using ISIS 183750; Irinotecan

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer.
ISIS 183750; Irinotecan

Advanced Solid Tumor Clinical Trial using LDE225; Wafarin; Bupropion

Novartis - Recruiting 18 years or older.
- A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors.
LDE225; Wafarin; Bupropion

Neoplasms Clinical Trial using PF-06263507

Pfizer - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors.
PF-06263507

Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, or Esophag Clinical Trial using GS-5745 monotherapy and in combination with chemotherapy

Gilead Sciences - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors.
GS-5745 monotherapy and in combination with chemotherapy

Solid Tumors, or Non-small Cell Lung Cancer Clinical Trial using oral 5-azacitidine in combination with romidepsin

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer.
oral 5-azacitidine in combination with romidepsin

Cancer Clinical Trial using GSK2256098; Trametinib

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors.
GSK2256098; Trametinib

Cancer Clinical Trial using GSK2849330

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors.
GSK2849330

Neoplasms Clinical Trial using 4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.
4 mg/kg Onartuzumab (MetMAb); 15 mg/kg Onartuzumab (MetMAb); 30 mg/kg Onartuzumab (MetMAb)

Neoplasm Metastasis Clinical Trial using LY2940680

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors.
LY2940680

Solid Tumors, Hematologic Malignancies, or Hepatic Impairment Clinical Trial using Carfilzomib

Onyx Pharmaceuticals - Recruiting 18 years or older.
- An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment.
Carfilzomib

Solid Tumors, or Non-small Cell Lung Carcinoma Clinical Trial using DS-2248

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors.
DS-2248

Solid Tumors Clinical Trial using MEDI4736; Tremelimumab

Ludwig Institute for Cancer Research - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors.
MEDI4736; Tremelimumab

Advanced Solid Tumors Clinical Trial using PRI-724

Prism Pharma Co., Ltd. - Recruiting 18 years or older.
- A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors.
PRI-724

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using methoxyamine; temozolomide; DNA analysis; laboratory biomarker analysis; pharmacological study

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors.
methoxyamine; temozolomide; DNA analysis; laboratory biomarker analysis; pharmacological study

Advanced Cancers, or Solid Tumors Clinical Trial using Erlotinib; Pralatrexate

M.D. Anderson Cancer Center - Recruiting 12 years or older.
- A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer.
Erlotinib; Pralatrexate

Diffuse Large B Cell Lymphoma Clinical Trial using E7438

Eisai Inc. - Recruiting 18 years or older.
- An Open-Label, Multicenter, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas.
E7438

Solid Tumors Clinical Trial using ARQ 761

University of Texas Southwestern Medical Center - Recruiting 18 years or older.
- A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors.
ARQ 761

Advanced Cancers, or Lymphoma Clinical Trial using NC-4016

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma.
NC-4016

Advanced Solid Tumors, Kidney Disease, or Renal Impairment Clinical Trial using AMG 386 + Paclitaxel; AMG 386

Amgen - Recruiting 18 years or older.
- An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function.
AMG 386 + Paclitaxel; AMG 386

Major Advanced Solid Tumors Other Than Colorectal Clinical Trial using PM01183

PharmaMar - Recruiting 18 years or older.
- Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 on Days 1 and 8 Every Three Weeks (q3wk) in Non-Colorectal Cancer (Non-CRC) Patients.
PM01183

Endometrial Adenocarcinomas, Neuroendocrine Tumors, or Small-cell Clinical Trial using lurbinectedin (PM01183); Doxorubicin

PharmaMar - Recruiting 18 years to 75 years.
- Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors.
lurbinectedin (PM01183); Doxorubicin

Solid Tumors Clinical Trial using nesvacumab (REGN910/ SAR307746); aflibercept (ziv-aflibercept)

Regeneron Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies.
nesvacumab (REGN910/ SAR307746); aflibercept (ziv-aflibercept)

Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-posit Clinical Trial using veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors.
veliparib; paclitaxel; carboplatin; pharmacological study; laboratory biomarker analysis

Solid Tumors Clinical Trial using patritumab

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors.
patritumab

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

Solid Tumors Clinical Trial using MSB0010718C

Merck KGaA - Recruiting 20 years or older.
- A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer.
MSB0010718C

Solid Tumors, Untreated Pancreatic Adenocarcinoma, Pancreatic Can Clinical Trial using PLX7486-TsOH; gemcitabine; nab-Paclitaxel

Plexxikon - Recruiting 18 years or older.
- A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent and in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors.
PLX7486-TsOH; gemcitabine; nab-Paclitaxel

At This Time, All Cohorts Are Closed to Enrollment With the Excep Clinical Trial using PLX3397

Plexxikon - Recruiting 18 years or older.
- A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients With Advanced, Incurable, Solid Tumors in Which the Target Kinases Are Linked to Disease Pathophysiology.
PLX3397

Solid Tumours Clinical Trial using dabrafenib; trametinib

GlaxoSmithKline - Recruiting 20 years or older.
- A Japanese Open-label Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of GSK2118436 and GSK1120212 Combination Therapy in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) and BRAF V600E/K Mutation Positive Cutaneous Melanoma (Phase II Part)..
dabrafenib; trametinib

Solid Tumor Clinical Trial using ARQ 087

ArQule - Recruiting 18 years or older.
- A Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors.
ARQ 087

Advanced Solid Tumors Clinical Trial using ARQ 197 as monotherapy or in combination with other drug(s)

ArQule - Recruiting N/A or older.
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.
ARQ 197 as monotherapy or in combination with other drug(s)

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using alisertib; gemcitabine

University of California, Davis - Recruiting 18 years or older.
- Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer.
alisertib; gemcitabine

Advanced Cancers (Solid Tumors) Clinical Trial using GL-ONC1

Genelux Corporation - Recruiting 18 years or older.
- Phase I Study of the Safety, Tolerability,and Tumor-Specific Replication of the Intravenous Administration of Green Fluorescent Protein Encoded Genetically Engineered Attenuated Vaccinia Virus, GL-ONC1, in Patients With Advanced Solid Organ Cancers..
GL-ONC1

Advanced Solid Tumours Clinical Trial using WX-037; WX-554

Wilex - Recruiting 18 years or older.
- A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors.
WX-037; WX-554

Advanced Solid Tumors Clinical Trial using E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Eisai Inc. - Recruiting N/A or older.
- An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Non Small Cell Lung Cancer Clinical Trial using decitabine in combination with genistein

Uman Pharma - Recruiting 18 years to 75 years.
- A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects.
decitabine in combination with genistein

Solid Tumors Clinical Trial using OTX008

OncoEthix - Recruiting 18 years or older.
- A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors.
OTX008

Advanced Solid Tumors Clinical Trial using Tesetaxel

Genta Incorporated - Recruiting 20 years or older.
- A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects With Advanced Solid Tumors.
Tesetaxel

Advanced Solid Tumors Clinical Trial using sapacitabine and seliciclib

Cyclacel Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors.
sapacitabine and seliciclib

Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Clinical Trial using CX-4945 oral formulation

Cylene Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma.
CX-4945 oral formulation

Advanced Solid Tumors Clinical Trial using M2ES 7.5mg; M2ES 15mg; M2ES 30mg; M2ES 60mg

Protgen Ltd - Recruiting 18 years to 65 years.
- Dose Escalation and PK Study of M2ES in Subjects With Advanced Solid Tumors.
M2ES 7.5mg; M2ES 15mg; M2ES 30mg; M2ES 60mg

Solid Tumors Clinical Trial using Lapatinib and Sorafenib

Istituto Clinico Humanitas - Recruiting 18 years or older.
- Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors.
Lapatinib and Sorafenib

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Hydroxychloroquine in Combination With Temozolomide in Patients With Advanced Solid Tumors.
hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study